Mid‑stage data for petrelintide, an amylin analogue developed by Zealand Pharma with Roche, produced a mean placebo‑controlled weight loss of about 9.0% (10.7% absolute at 42 weeks), below investor expectations tied to peer candidates. Investors sold off Zealand shares on the magnitude gap versus rivals, though the companies emphasized a favorable tolerability profile. Zealand characterized the profile as a positive combination of safety and efficacy and said it still plans a Phase III program, while analysts questioned the drug’s ability to differentiate in a crowded obesity market.